re: gone Its still above issue price, for a company that will miss prospectus numbers (on NPAT basis) by 20-25%....there's still potential for more downside on that basis alone.
Revised FY05 NPAT is now $9.9M. Market Cap is $143.5M (@ $1.60), that puts it on a FY05 PE Multiple of 14.5 times.
For a no-growth (or at best very smal growth) company, that's probably too high.
I don't hold.
- Forums
- ASX - By Stock
- selling all but gone dry
LIP
lipa pharmaceuticals limited
re: gone Its still above issue price, for a company that will...
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)